Therapy News and Research

RSS

Study finds no evidence that stem cell therapy improves vision for children with ONH

A study performed at Children's Hospital Los Angeles found no evidence that stem cell therapy improves vision for children with optic nerve hypoplasia. Their results are reported in the Journal of the American Association for Pediatric Ophthalmology and Strabismus.

22 Oct 2013

Risk for breast cancer: Key prevention awareness tips for young women

Breast cancer prevention needs to become a shared conversation among women of all ages as it can strike at any age, and is generally more aggressive when diagnosed in women under the age of 50. With hopes to spark that discussion, Isabelle Mercier, PhD, a research assistant professor at University of the Sciences, compiled some key prevention awareness tips for young women.

22 Oct 2013

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Breast milk may protect babies from acquiring HIV infection, say researchers

A substance in breast milk that neutralizes HIV and may protect babies from acquiring HIV from their infected mothers has been identified for the first time by researchers at Duke Medicine.

22 Oct 2013

Study opens doors to novel treatments for aggressive brain cancer

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

22 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

$Adalimumab may be viable treatment option for patients with refractory pediatric uveitis$

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients with steroid-resistant refractory pediatric uveitis.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

UH professor awarded $1.56M NCI grant to explore preventive therapy against colon cancer

As the second leading cause of cancer-related deaths in the U.S., colon cancer affects both men and women and is expected to cause more than 50,000 deaths this year. University of Houston professor Cecilia Williams has been awarded a $1.56 million grant from the National Cancer Institute to investigate the mechanistic basis for novel colon cancer prevention and therapy.

22 Oct 2013

Kona Medical closes Series D equity financing of $10 million

Kona Medical, Inc. today announced it has closed a Series D equity financing of $10 million. Morningside Group, a broad-based investment firm with significant presence in China, led the investment and is the sole investor.

21 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome.

21 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children's Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular atrophy (SMA).

19 Oct 2013

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing five new Research Units. This was decided by the DFG Senate at its October meeting. The purpose of the research collaborations is to offer researchers the possibility to pursue current, pressing issues in their subject areas and to establish innovative work directions.

19 Oct 2013

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market.

19 Oct 2013

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Each week, KHN compiles a selection of recently released health policy studies and briefs.

19 Oct 2013

Therapy News and Research

Study finds no evidence that stem cell therapy improves vision for children with ONH

Risk for breast cancer: Key prevention awareness tips for young women

Clinical trials will help to develop treatment and follow-up of COPD patients

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Breast milk may protect babies from acquiring HIV infection, say researchers

Study opens doors to novel treatments for aggressive brain cancer

Pancreatic cancer patients may benefit from antibody-drug conjugates

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

UH professor awarded $1.56M NCI grant to explore preventive therapy against colon cancer

Kona Medical closes Series D equity financing of $10 million

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News